Hospital
Franciscan Health System
Franciscan Health System was paid $14.31M by Medicaid between Jan 2018 and Dec 2024, across 214 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 17% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH SYSTEM
GIG HARBOR, WA 98332
GIG HARBOR, WA 98332
33aNPI1447406699assigned 08/07/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.31M
24GClaims581,377
24DCodes billed214
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#31 of 49
Median peer was paid$20.06M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71,543 | $1.90M | |
| 2019 | 82,244 | $2.00M | |
| 2020 | 74,529 | $1.87M | |
| 2021 | 83,775 | $1.87M | |
| 2022 | 90,613 | $2.30M | |
| 2023 | 102,750 | $2.44M | |
| 2024incomplete | 75,923 | $1.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 8,128 | 6,655 | $2.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 20,403 | 19,240 | $2.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 21,601 | 19,783 | $1.84M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 11,245 | 10,394 | $1.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 5,834 | 5,594 | $1.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 6,629 | 6,317 | $598K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 4,023 | 3,837 | $559K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3.1% | 2,116 | 1,382 | $449K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 4,519 | 3,634 | $440K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 13,342 | 4,924 | $349K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 1,901 | 1,845 | $333K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 2,316 | 1,910 | $265K |
202 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 805 | $255K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 874 | $185K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,063 | $178K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 2,827 | $171K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 4,986 | $160K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,001 | $137K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,534 | $119K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,329 | $107K |
| 97161 | <1% | 2,413 | $102K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,526 | $101K |
| 76830 | Ultrasound, transvaginal | <1% | 1,244 | $99K |
| 76937 | <1% | 1,789 | $82K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,008 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 2,872 | $67K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,018 | $59K |
| 84484 | <1% | 12,641 | $52K | |
| 80053 | Comprehensive metabolic panel | <1% | 12,021 | $52K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 113 | $50K |
| 64493 | <1% | 79 | $48K | |
| 70496 | <1% | 247 | $46K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 375 | $36K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 506 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 775 | $32K |
| 80047 | <1% | 3,838 | $26K | |
| 80076 | <1% | 11,241 | $25K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,279 | $23K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,832 | $22K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 78 | $22K |
| 93971 | <1% | 276 | $21K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,065 | $21K |
| 87040 | <1% | 3,268 | $21K | |
| 83605 | <1% | 3,826 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,333 | $17K |
| 12001 | <1% | 86 | $16K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 210 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 70 | $16K |
| 85379 | <1% | 3,156 | $15K | |
| 95806 | <1% | 94 | $15K | |
| 64483 | <1% | 24 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,116 | $15K |
| 90715 | <1% | 770 | $14K | |
| 72100 | <1% | 984 | $13K | |
| 83880 | <1% | 3,091 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 866 | $11K |
| 10060 | <1% | 56 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,130 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,247 | $10K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,361 | $9K |
| 64635 | <1% | 12 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 40 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 779 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,277 | $8K |
| 73630 | <1% | 1,232 | $8K | |
| 97165 | <1% | 209 | $7K | |
| 84145 | <1% | 994 | $7K | |
| 73130 | <1% | 1,073 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,080 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,442 | $5K |
| 73030 | <1% | 996 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 45 | $5K |
| 70498 | <1% | 217 | $4K | |
| 80143 | <1% | 1,355 | $4K | |
| 73560 | <1% | 1,025 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 94 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 26 | $4K |
| 99195 | <1% | 336 | $4K | |
| 72040 | <1% | 212 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,739 | $3K |
| 73610 | <1% | 959 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,231 | $3K |
| 73502 | <1% | 384 | $3K | |
| 83735 | <1% | 4,188 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,670 | $3K |
| 93017 | <1% | 24 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,134 | $2K |
| 83690 | <1% | 13,257 | $2K | |
| 70486 | <1% | 66 | $2K | |
| 76536 | <1% | 24 | $2K | |
| 80179 | <1% | 1,272 | $2K | |
| 82962 | <1% | 7,862 | $2K | |
| 96367 | <1% | 38 | $2K | |
| 70491 | <1% | 12 | $2K | |
| 71250 | <1% | 38 | $2K | |
| 74018 | <1% | 268 | $2K | |
| 97116 | <1% | 120 | $2K | |
| 96376 | <1% | 5,346 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,535 | $2K |
| 93970 | <1% | 13 | $1K | |
| 73110 | <1% | 337 | $1K | |
| 81001 | <1% | 11,887 | $1K | |
| 84702 | <1% | 2,321 | $1K | |
| 84703 | <1% | 5,168 | $1K | |
| 85610 | <1% | 8,893 | $1K | |
| 87070 | <1% | 2,095 | $1K | |
| 87641 | <1% | 109 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,542 | $1K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 149 | $1K |
| 64494 | <1% | 66 | $924.07 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,164 | $896.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 10,658 | $850.41 |
| 85027 | <1% | 1,787 | $798.59 | |
| 84100 | <1% | 1,826 | $773.03 | |
| 82565 | <1% | 2,300 | $708.57 | |
| 72131 | <1% | 24 | $604.36 | |
| 76000 | <1% | 31 | $602.76 | |
| 81025 | <1% | 4,691 | $596.35 | |
| 81003 | <1% | 5,557 | $574.82 | |
| 87205 | <1% | 1,465 | $560.70 | |
| 87430 | <1% | 1,142 | $552.15 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 867 | $542.75 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,145 | $510.22 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,500 | $477.04 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,207 | $453.99 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,341 | $443.19 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 324 | $376.74 |
| 80051 | <1% | 1,741 | $372.75 | |
| 74022 | <1% | 126 | $362.93 | |
| 85014 | <1% | 299 | $358.91 | |
| 82330 | <1% | 2,356 | $336.02 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,057 | $319.16 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,461 | $294.29 |
| C1769 | Guide wire | <1% | 126 | $267.79 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,020 | $251.38 |
| 73070 | <1% | 47 | $251.18 | |
| 87186 | <1% | 2,032 | $237.53 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,685 | $215.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,910 | $213.91 |
| 86140 | <1% | 380 | $205.27 | |
| 73590 | <1% | 56 | $166.19 | |
| 86900 | <1% | 663 | $154.99 | |
| 0240U | <1% | 317 | $151.12 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,369 | $147.37 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 293 | $143.06 |
| 82075 | <1% | 149 | $131.34 | |
| 90686 | <1% | 12 | $129.81 | |
| 85651 | <1% | 543 | $127.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 808 | $113.16 |
| 82803 | <1% | 349 | $104.26 | |
| 86901 | <1% | 735 | $101.88 | |
| 86850 | <1% | 362 | $100.03 | |
| 82553 | <1% | 18 | $97.29 | |
| 82947 | <1% | 1,687 | $96.82 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 161 | $93.05 |
| 87077 | <1% | 553 | $88.86 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,057 | $77.25 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 44 | $72.87 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 220 | $71.18 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,108 | $65.20 |
| 85730 | <1% | 311 | $55.72 | |
| 94760 | <1% | 112 | $48.70 | |
| 88304 | <1% | 96 | $47.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,805 | $42.48 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 274 | $42.47 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 770 | $41.42 |
| 82550 | <1% | 143 | $40.82 | |
| 73140 | <1% | 14 | $39.38 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,562 | $38.82 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,909 | $37.46 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $30.75 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 74 | $29.84 |
| 84132 | <1% | 20 | $24.36 | |
| 81002 | <1% | 224 | $21.12 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,076 | $19.02 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,144 | $17.79 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 717 | $15.62 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 224 | $11.97 |
| A9270 | Non-covered item or service | <1% | 18,221 | $11.89 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 829 | $8.46 |
| 82270 | <1% | 12 | $8.23 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,181 | $7.19 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 621 | $2.61 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 475 | $0.52 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,309 | $0.04 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 54 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 95 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 399 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 784 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 94 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 109 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 97 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 94 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 102 | $0.00 |
| 76942 | 0% | 13 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 25 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 13 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 30 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 106 | $0.00 |
| 88307 | 0% | 100 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 52 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 119 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 72 | $0.00 |
| 87147 | 0% | 14 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 12 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 112 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 44 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 16 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 36 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 201 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 31 | $0.00 |
| 88342 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILCZEK, JOSEPH (CEO)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Health System | Tacoma, WA | $44.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.